BRISBANE, Calif., June 09, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the first quarter ended March 31, 2017.
"We are very pleased with our progress towards AlloSure reimbursement and look forward to soon being able to provide the first and only non-invasive test that uses donor-derived cell free DNA to directly measure organ health and identify the probability of active transplant rejection,” said Peter Maag, CareDx President and Chief Executive Officer. "AlloMap test volume growth has continued, reflecting our reach into the transplant center community and patients.”
"We are very pleased with our progress towards AlloSure reimbursement and look forward to soon being able to provide the first and only non-invasive test that uses donor-derived cell free DNA to directly measure organ health and identify the probability of active transplant rejection,” said Peter Maag, CareDx President and Chief Executive Officer. "AlloMap test volume growth has continued, reflecting our reach into the transplant center community and patients.”
